Atomoxetine Hydrochloride/Oxybutynin

盐酸托莫西汀/奥昔布宁

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAtomoxetine Hydrochloride/Oxybutynin
Drug Alias NameAtomoxetine Hydrochloride+Oxybutynin奥昔布宁/盐酸托莫西汀盐酸托莫西汀+奥昔布宁Oxybutynin+Atomoxetine Hydrochloride奥昔布宁+盐酸托莫西汀 +[7] 
ClassificationSmall molecules
Mechanisms of ActionNorepinephrine reuptake inhibitorsMuscarinic acetylcholine receptor antagonists
TargetsNorepinephrine transporterMuscarinic acetylcholine receptor
Therapy Area/IndicationsDown SyndromeSleep Apnea, ObstructiveSleep Apnea Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsYes Atomoxetine HydrochlorideOxybutynin
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesApnimed Inc
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalApnimed IncThe University Of Arizona
Inactive CompaniesN/A
Active IndicationsDown SyndromeSleep Apnea, ObstructiveSleep Apnea Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A